Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer

Dendritic cell biology and its role in tumor immunotherapy

(2020) Yingying Wang et al.   Journal of Hematology & Oncology

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

(2019) James L. Gulley et al.   JOURNAL OF CLINICAL ONCOLOGY

Blocking PD-1/PD-L1 in Genitourinary Malignancies

(2018) Matthew C. Dallos et al.   CANCER JOURNAL

Systematic Review of Immune Checkpoint Inhibition in Urological Cancers

(2017) Maud Rijnders et al.   EUROPEAN UROLOGY

Unknown

(2015)   Oncotarget

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

(2008) Dominik R. Berthold et al.   JOURNAL OF CLINICAL ONCOLOGY